Dermal leishmaniasis and rifampicin.
In an uncontrolled study, the effectiveness of rifampicin was assessed in cutaneous leishmaniasis. Twelve of 15 patients (80%) showed good response. The treatment ranged from 2 to 12 weeks. Tolerance of the drug was excellent and apart from red discolouration of the urine, no other side effects were encountered. Rifampicin appears to have a place in the management of cutaneous leishmaniasis.
Joshi
R K
RK
Department of Dermatology, Al-Huwaylat Hospital, Jubail Industrial City, Saudi Arabia.
Nambiar
P M
PM
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007896:Leishmaniasis / Q000188:drug therapy*; D008297:Male; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*
D012293:Rifampin